Is trastuzumab weight based dosing?

Trastuzumab, a key treatment for HER2-positive breast cancer, is available in weight-based IV and fixed-dose (600 mg) SC formulations.

How is trastuzumab dosed?

Administer Herceptin at an initial dose of 8 mg/kg as a 90-minute intravenous infusion followed by subsequent doses of 6 mg/kg as an intravenous infusion over 30–90 minutes every three weeks until disease progression [see Important Dosing Considerations].

Does trastuzumab cause weight gain?

Symptoms to watch for include swelling of the ankles or legs, shortness of breath, cough, or weight gain of more than 5 pounds in less than 24 hours. Contact your doctor immediately if you have any of these symptoms.

Does trastuzumab need to be refrigerated?

Stability and Storage: Vials of Herceptin are stable at 2–8°C (36–46°F) prior to reconstitution. Do not use beyond the expiration date stamped on the vial. A vial of Herceptin reconstituted with BWFI, as supplied, is stable for 28 days after reconstitution when stored refrigerated at 2–8°C (36–46°F).

Do you dilute trastuzumab?

Using a sterile syringe, slowly inject the 20 mL of diluent into the vial containing the lyophilized cake of Herceptin. The stream of diluent should be directed into the lyophilized cake. Swirl the vial gently to aid reconstitution. DO NOT SHAKE.

What is the side effects of trastuzumab?

Common side effects of Herceptin include:

• diarrhea,
• redness or irritation at injection (IV) site,
• muscle/joint/back pain,
• stomach or abdominal pain,
• headache,
• sleep problems (insomnia),
• nausea and vomiting (may be severe),
• weight loss,

Does trastuzumab cause hair loss?

Answer: No, hair loss is not a common side effect of trastuzumab. If you are receiving trastuzumab in combination with chemotherapy, you may experience hair loss due to the chemotherapy.

What are the side effects of trastuzumab?

The most common side effects seen in treatment of metastatic breast cancer (based on intravenous trastuzumab) are fever, chills, headache, infection, congestive heart failure, insomnia, cough, and rash.

What is trastuzumab injection?

Trastuzumab is used to treat certain types of breast, stomach, or esophagus cancer. This medication is used to treat tumors that produce more than the normal amount of a certain substance called HER2 protein. Trastuzumab belongs to a class of medications known as monoclonal antibodies.

Is trastuzumab a pill?

Is trastuzumab SC fixed dose equivalent to IV administration in obese patients?

These differences are especially greater in T-SC patients with BMI >30 kg/m 2, with only 20% of patients exceeding the pharmacokinetic target. Conclusion and Relevance: Our study suggests that trastuzumab SC fixed dose of 600 mg is not equivalent to IV administration, especially in obese patients.

What are the risks of trastuzumab in overweight patients?

Trastuzumab levels may not reach target with the first dose in overweight patients. Low body weight does not seem to increase cardiotoxicity risk with SC trastuzumab. Adverse event rates were higher with SC than IV trastuzumab in Phase 3 trials. The risks and benefits of IV vs SC trastuzumab should be discussed with the patient.

How is the Cmin of trastuzumab determined?

The determination of the Cmin of trastuzumab was performed on day +21 of the first cycle using the ELISA technique. Patients were stratified according to the strategy of dosification and BMI. Results: A total of 50 patients were included; 16 patients received the drug intravenously and 34 in a fixed dosage subcutaneous (T-SC) regimen.

Does trastuzumab increase the incidence of NCI-CTC grade 3-4 neutropenia?

In randomized, controlled clinical trials with intravenous trastuzumab, the per-patient incidences of NCI-CTC Grade 3-4 neutropenia and of febrile neutropenia were higher in patients receiving trastuzumab in combination with myelosuppressive chemotherapy as compared to those who received chemotherapy alone.